Russian biotech developer reports good clinical trial results for its HIV drug

Viriom, a Moscow-based biotech developer, has announced positive results of the latest international clinical trial testing of its innovation drug to fight the HIV

Viriom, a Moscow-based biotech developer, has announced positive results of the latest international clinical trial testing of its innovation drug to fight the HIV, Rusnanonet.ru reported. During the testing, its VM-1500 drug candidate is said to have demonstrated ?unique pharmacokinetic properties and, unlike other drug candidates in this pharma class, strong resistance to the HIV,? the source quoted a company spokesman as saying. According to Dr. Vadim Bychko, the scientific director of Viriom, this round of clinical trials was conducted in Russia and Thailand and has revealed that the VM-1500 is ?safe, produces no negative effect on healthy volunteers and chronic HIV-1 patients alike after both one-time and multiple peroral administering of the substance, and also shows favorable pharmacokinetics.? The results that have been obtained in the two countries give Viriom grounds to believe that the VM-1500 ?has the potential to become the best in its class,? Dr...